IVUS-Guided vs Angiography-Guided PCI in Patients With Diabetes With Acute Coronary Syndromes
JACC: Cardiovascular Interventions · 2025-02 · 18 (3) · 283-293
DOI: 10.1016/j.jcin.2024.09.061 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JACC: Cardiovascular Interventions, 2025-02. Verfasst von Xiaofei Gao und 11 weiteren Autor:innen. Beteiligte Einrichtung: Nanjing First Hospital, Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Ultrasonography, Interventional, Percutaneous Coronary Intervention, Acute Coronary Syndrome, Coronary Angiography. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
BACKGROUND: Intravascular ultrasound (IVUS)-guided percutaneous coronary intervention (PCI) reduces the risk for clinical events in patients with acute coronary syndromes (ACS), compared with angiographic guidance. However, the benefits of IVUS guidance in high-risk patients with diabetes with ACS is uncertain. OBJECTIVES: The aim of this prespecified stratified subgroup analysis from the IVUS-ACS randomized trial was to determine the effectiveness of IVUS-guided PCI vs angiography-guided PCI in patients with diabetes with ACS. METHODS: From August 20, 2019, to October 27, 2022, 1,105 patients with diabetes with ACS were randomized, including 554 patients in the IVUS-guided group and 551 in the angiography-guided group. The primary endpoint was the rate of target vessel failure (TVF) at 1 year, defined as the composite of cardiac death, target vessel myocardial infarction, or clinically driven target vessel revascularization. RESULTS: At 1-year follow-up, TVF occurred in 20 patients in the IVUS guidance group and in 46 patients in the angiographic guidance group (Kaplan-Meier rates 3.6% vs 8.3%; HR: 0.46; 95% CI: 0.27-0.81; P = 0.007), driven by a reduction in clinically driven target vessel revascularization (0.9% vs 3.8%; P = 0.003). IVUS-guided PCI also reduced the risk for TVF without procedural myocardial infarction (2.0% vs 6.7%; HR: 0.29; 95% CI: 0.15-0.57; P < 0.001) and all-cause mortality (HR: 0.30; 95% CI: 0.10-0.93; P = 0.037). There were no significant differences in the rates of stent thrombosis or major bleeding between the groups. CONCLUSIONS: In the large-scale IVUS-ACS trial, IVUS-guided PCI improved 1-year clinical outcomes in high-risk patients with diabetes with ACS. (1-Month vs 12-Month DAPT for ACS Patients Who Underwent PCI Stratified by IVUS: IVUS-ACS and ULTIMATE-DAPT Trials; NCT03971500).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
- Punjab Institute of Cardiology, Lahore, Pakistan.
- Xiamen Heart Center, Xiamen University, Xiamen, China.
- People's Hospital of Wuhan University, Wuhan, China.
- Pederzoli Hospital, Peschiera del Garda, Verona, Italy.
- Cardiovascular Research Foundation, New York, New York, USA.
Zitieren
APA
Gao, X., Kan, J., Wu, Z., Anjum, M., Chen, X., Chen, J., Sheiban, I., Mintz, G. S., Zhang, J. J., Stone, G. W., Chen, S. L., & IVUS-ACS Investigators (2025). IVUS-Guided vs Angiography-Guided PCI in Patients With Diabetes With Acute Coronary Syndromes. JACC: Cardiovascular Interventions, 18(3), 283-293. https://doi.org/10.1016/j.jcin.2024.09.061
Vancouver
Gao X, Kan J, Wu Z, Anjum M, Chen X, Chen J, et al. IVUS-Guided vs Angiography-Guided PCI in Patients With Diabetes With Acute Coronary Syndromes. JACC: Cardiovascular Interventions. 2025;18(3):283-293. doi:10.1016/j.jcin.2024.09.061
BibTeX
@article{Gao2025,
author = {Gao, Xiaofei and Kan, Jing and Wu, Zhiming and Anjum, Muhammad and Chen, Xiang and Chen, Jing and Sheiban, Imad and Mintz, Gary S and Zhang, Jun-Jie and Stone, Gregg W and Chen, Shao-Liang and IVUS-ACS Investigators, IVUS-ACS Investigators},
title = {IVUS-Guided vs Angiography-Guided PCI in Patients With Diabetes With Acute Coronary Syndromes},
journal = {JACC: Cardiovascular Interventions},
year = {2025},
volume = {18},
number = {3},
pages = {283--293},
doi = {10.1016/j.jcin.2024.09.061}
}
EUVIMED